ClinicalTrials.gg
CompletedNCT04076813CAMEOUpdated Oct 28, 2026

Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

An observational study in Myocardial Infarction, sponsored by Chiesi USA, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Chiesi USA, Inc. (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

Updated Oct 28, 2026Now CompletedResults publication added+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
5,050
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Myocardial Infarction with a site in United States — 41 open to participants now, 65 under way, 9 of them phase 3. Myocardial Infarction · United States.

Enrollment
32nd of 136
5,050 · median 514
Started
2019
with 12 others
Observational
136 of 440
13 open now
Registered
338th of 440
by date

Among the 440 studies in Myocardial Infarction with a site in United States, this one is the 32nd largest by enrollment of the 136 observational ones that give a count, is one of 13 that started in 2019, is one of 136 observational ones, and was the 338th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

41 of the 440 studies in Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Myocardial Infarction with a site in United States, or all of them as a file.
02

Study summary

The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.

Read the detailed description

The CAMEO registry is a multicenter observational registry that will collect information on approximately 5,050 patients with NSTEMI or STEMI treated with cangrelor or an oral P2Y12 inhibitor into the registry.

Phase 1: Each site will abstract data from the medical record for the first 50 patients meeting the inclusion and exclusion criteria treated at the hospital within 4 months prior to study initiation or during the study period.

Phase 2: After Phase 1, all cangrelor-treated patients meeting the inclusion and exclusion criteria will be entered into the registry, and we will begin sampling non-cangrelor patients in a 2:1 cangrelor: non-cangrelor ratio (Phase 2) up to 3000 patients.

Phase 3: We will work with sites on a quality improvement initiative with the current sites to 1) continue enrollment of an additional 2,000 patients; 2) provide feedback reports to both the sites and operators about the use and administration of cangrelor to patients they are treating; 3) utilize a pharmacist-based group with representatives from each site to identify opportunities to improve use of cangrelor according to the established treatment strategy.

03

Conditions studied

  • Myocardial Infarction

Keywords

  • cangrelor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

≥ 18 years of age and underwent coronary angiography for a STEMI or NSTEMI.

Eligibility criteria

Phase 1 Inclusion Criteria:

For the first 50 patients at each participating site, consecutive patients are entered in the registry if they are ≥ 18 years of age, underwent coronary angiography for a STEMI or NSTEMI, and received cangrelor at any time during the hospitalization or an oral P2Y12 inhibitor during his/her first 48 hours of the hospitalization for MI.

Phase 2 Inclusion Criteria:

Subsequent patients are eligible to be entered in the registry if they are ≥ 18 years of age and underwent coronary angiography for a STEMI or NSTEMI and meet at least 1 of the following criteria:

  1. The patient was hospitalized for STEMI and met one of the following inclusion criteria:

    • The patient received cangrelor at any time during his/her hospitalization for MI.
    • The patient received an oral P2Y12 inhibitor during his/her first 48 hours of hospitalization AND either of the following:
    • The patient received a P2Y12 inhibitor and an opiate/opioid within 24 hours prior to or during primary PCI for STEMI presentation.

    OR

    • The patient underwent coronary angiography followed by CABG during the index MI admission and received any P2Y12 inhibitor within 7 days prior to CABG.
  2. The patient was hospitalized for NSTEMI and met one of the following inclusion criteria:

    • The patient received cangrelor during his/her hospitalization for MI.
    • The patient received an oral P2Y12 inhibitor during his/her first 48 hours of hospitalization AND either of the following:
    • The patient underwent coronary angiography followed by CABG during the index MI admission and received any P2Y12 inhibitor within 7 days prior to CABG. OR
    • Any 2 of the following criteria without prior PCI or CABG: age> 60 years, male sex, diabetes, EF \<40% prior heart failure

Exclusion Criteria: If the patient does not meet the inclusion criteria for either Phase.

Phase 3 Eligibility Criteria:

The Phase 3 portion of the CAMEO registry will focus on launching local site quality improvement initiatives with the goal of optimizing cangrelor usage according to FDA-approved established treatment strategy. Enrollment for the registry will be extended for an additional two years to include an additional 2,000 patients in this phase of the registry. The inclusion criteria of these patients will be the same as in Phase 2 (see section 3.3.2). We will also capture which patients are cared for at each site by individual operators. Operator-level data will be de-identified, and each operator will be assigned an operator ID. Sites will be asked to maintain a crosswalk for operator ID, and complete an operator characteristics survey. The operator characteristics survey will ask questions around age, sex, and other relevant operator characteristics, and will be used in the analysis phase in aggregate. Operators will not be directly identified and the analytics center will not have access to the crosswalk, which will be maintained at the site.

We will identify a pharmacist representative at each site to form a pharmacist-based group who meets monthly to identify strategies to improve processes at each site and to improve use of cangrelor in the MI population according to the established treatment strategy. We will present quarterly feedback reports to the sites that include data regarding the use of cangrelor according to the following parameters: 1) administration of both a bolus and infusion; 2) appropriate timing between infusion and initiation of oral PY212 inhibitor therapy; 3) and administration of the infusion based on clinical trial data and dose package labeling for patients who are able to be transitioned to oral P2Y12 inhibitor therapy shortly after PCI.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
5,050 participants (actual)
Patient registry
No

Groups and cohorts

  • STEMI/NSTEMI

    Patients in the registry will be 18 years of age or older and underwent coronary angiography for a ST-elevation myocardial infarction (STEMI) or NSTEMI Non-ST-elevation myocardial infarction

06

What researchers measure

Primary outcomes

  1. The number of Antiplatelet medications used during hospitalization

    Antiplatelet use, including switching and discontinuation will be measured by medical record report. The medical record report will include medication start and stop dates and times.

    Time frame: The time frame is hospitalization through discharge, approximately 3 days

  2. Number of bleeding events during hospitalization as measured by medical record report

    Bleeding event entered from the medical record report.

    Time frame: The time frame is hospitalization, up to 7 days post discharge

07

Study locations

11 sites
  • The Regents of the University of California on behalf of its San Diego campus
    La Jolla, California 92093, United States
  • Christiana Care Health Services, Inc.
    Newark, Delaware 19713, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • Kootenai Hospital District dba Kootenai Health
    Coeur d'Alene, Idaho 83814, United States
  • MedStar Health Research Institute, Inc.
    Hyattsville, Maryland 20782, United States
  • The Brigham and Women's Hospital, Inc.
    Boston, Massachusetts 02115, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • The Trustees of Columbia University in the City of New York
    New York, New York 10032, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37323, United States
08

References and documents

Publications

  • Rymer JA, Page C, Alhanti B, Narcisse D, Washam J, Ang L, Bach R, Wimmer N, Kochar A, El-Sabae H, Angiolillo DJ, Bhatt D, Chaturvedi A, Waksman R. TCT-299 cangrelor use in acute myocardial infarction patients awaiting coronary artery bypass grafting. Journal of the American College of Cardiology. 2024;84(18):B68-B69. doi:10.1016/j.jacc.2024.09.353
  • Rymer JA, Bhatt DL, Angiolillo DJ, Diaz M, Garratt KN, Waksman R, Edwards L, Tasissa G, Salahuddin K, El-Sabae H, Dell'Anna C, Davidson-Ray L, Washam JB, Ohman EM, Wang TY. Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry. J Am Heart Assoc. 2022 Jun 7;11(11):e024513. doi: 10.1161/JAHA.121.024513. Epub 2022 May 27. PubMed 35621210 ↗
  • Rymer J, Alhanti B, Kemp S, Bhatt DL, Kochar A, Angiolillo DJ, Diaz M, Garratt KN, Wimmer NJ, Waksman R, Kirtane AJ, Ang L, Bach R, Barker C, Jenkins R, Basir MB, Sullivan A, El-Sabae H, Brothers L, Ohman EM, Jones WS, Washam JB, Wang TY. Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y12 Inhibitor Therapy: The CAMEO Registry. J Soc Cardiovasc Angiogr Interv. 2023 Nov 27;3(2):101202. doi: 10.1016/j.jscai.2023.101202. eCollection 2024 Feb. PubMed 39132213 ↗
  • Rymer J, Pichan C, Page C, Alhanti B, Bhatt DL, Kochar A, Angiolillo DJ, Diaz M, Wimmer NJ, Waksman R, Ang L, Bach R, Jenkins R, El-Sabae H, Brothers L, Ohman EM, Jones WS, Washam JB, Wang TY, Narcisse D, Basir MB. The Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry. J Card Fail. 2024 Oct;30(10):1233-1240. doi: 10.1016/j.cardfail.2024.08.003. PubMed 39389732 ↗

Individual participant data

Plan to share: No — There is not a current plan to share IPD.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2019 to primary completion in Nov 2025, 73 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jun 2025 → Nov 2025 and completion Jun 2025 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2019
First posted
Sep 3, 2019
StartActual
Oct 16, 2019
Primary completionActual
Nov 24, 2025was Jun 2025
CompletionActual
Dec 15, 2025was Jun 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 28, 2026
Sites
1 site added, 1 site removed
Show site
  • Washington University · St Louis, United States
Show 1 removed
  • Washington University · St. Louis, United States
Oct 28, 2026
Primary completion
Jun 30, 2025→Nov 24, 2025 (actual)
Oct 28, 2026
Study completion
Jun 30, 2025→Dec 15, 2025 (actual)
Oct 28, 2026
Publications
Results publication added: Rymer JA, Page C, Alhanti B, Narcisse D, Washam J, Ang L, Bach R, Wimmer N, Kochar A, El-Sabae H, Angiolillo DJ, Bhatt D, Chaturvedi A, Waksman R. TCT-299 cang…
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Active, not recruiting→Completed
    Publications Results publication added: Rymer JA, Page C, Alhanti B, Narcisse D, Washam J, Ang L, Bach R, Wimmer N, Kochar A, El-Sabae H, Angiolillo DJ, Bhatt D, Chaturvedi A, Waksman R. TCT-299 cang…
    1 site added, 1 site removed
    Show site
    • Washington University · St Louis, United States
    Show 1 removed
    • Washington University · St. Louis, United States
    Primary completion Jun 30, 2025→Nov 24, 2025 (now actual)
    Study completion Jun 30, 2025→Dec 15, 2025 (now actual)
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04076813
Lead sponsor
Chiesi USA, Inc.
Collaborators
Duke University
Responsible party
Sponsor
First posted
Sep 3, 2019
Start date
Oct 16, 2019
Primary completion
Nov 24, 2025
Completion
Dec 15, 2025
Last update
Oct 28, 2026

Study contacts

Jennifer Rymer, MD
principal investigator · Duke University
Jeffrey Washam
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion